retatrutide safety trial Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Trial of next-gen weight-loss drug

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily licensed for the management of type 2 diabetes mellitus and, in specific cases, for weight management

Let me eggs-plain, with the help of this review

Notably, genome-wide association study (GWAS) analyses for body mass index (BMI) have linked glutamatergic signalling and NMDA receptor-related neuroplasticity to regulation of body weight and obesity 1,5

Watch our webinar, Emerging clinical applications for GLP-1 receptor agonists, to learn more

32 and HRP-labeled secondary antibody (immunogen-affinity purified,1:5000 dilution in CanGetSignal solution 2)